نتایج جستجو برای: alflutinib mesylate tablets

تعداد نتایج: 18521  

Journal: :Acta pharmaceutica 2014
Bahia Abbas Moussa Marianne Alphonse Mahrouse Mahmoud Ali Hassan Michael Gamal Fawzy

Quinone-based fluorophores and enhanced native fluorescence techniques were applied for a fast quantitative analysis of gemifloxacin mesylate (GEM) and linezolid (LIN) in pharmaceutical formulations. For this purpose, three sensitive, accurate and precise spectrofluorimetric methods were developed. GEM, as an n-electron donor, reacts with 7,7,8,8-tetracyanoquinodimethane (method A) and 2,5-dich...

2013
Noha N. Atia Ashraf M. Mahmoud Salwa R. El-Shabouri Wesam M. El-Koussi

Two new, sensitive, and selective spectrofluorometric methods were developed for the determination of gemifloxacin mesylate (GFX) in tablets and spiked human plasma. Method A was based on measurement of the enhanced fluorescence spectral behaviour of GFX in a sodium dodecyl sulphate (SDS) micellar system. In aqueous solution of acetate buffer pH 5.5, the fluorescence intensity of GFX was greatl...

Journal: :Journal of biochemistry and molecular biology 2005
Jungeun Park Sangmi Kim Jong K Oh Jin Y Kim Sung Soo Yoon Dongsoon Lee Youngsoo Kim

Resistance to imatinib mesylate (also known as Gleevec, Glivec, and STI571) often becomes a barrier to the treatment of chronic myelogenous leukemia (CML). In order to identify markers of the action of imatinib mesylate, we used a mass spectrometry approach to compare protein expression profiles in human leukemia cells (K562) and in imatinib mesylate-resistant human leukemia cells (K562-R) in t...

Journal: :Molecular cancer therapeutics 2014
Ziyan Y Pessetto Yan Ma Jeff J Hirst Margaret von Mehren Scott J Weir Andrew K Godwin

Gastrointestinal stromal tumor (GIST) is a rare and therefore often neglected disease. Introduction of the kinase inhibitor imatinib mesylate radically improved the clinical response of patients with GIST; however, its effects are often short-lived, with GISTs demonstrating a median time-to-progression of approximately two years. Although many investigational drugs, approved first for other can...

Journal: :Blood 2006
Hagop M Kantarjian Moshe Talpaz Susan O'Brien Daniel Jones Francis Giles Guillermo Garcia-Manero Stefan Faderl Farhad Ravandi Mary Beth Rios Jianqin Shan Jorge Cortes

A survival benefit for imatinib mesylate versus interferon-alpha therapy could not be demonstrated in the randomized study in newly diagnosed Philadelphia chromosome (Ph)-positive chronic-phase chronic myelogenous leukemia (CML) due to the high rate of crossover (90%) from interferon-alpha to imatinib mesylate within a year of study entry. We compared survival in 279 patients with newly diagnos...

A simple, precise, inexpensive and sensitive voltammetric method has been developed for the determination of gemifloxacin mesylate (GEM) in the presence of tween 80 in the bulk, farmaceutical dosage forms and human urine at gold nanoparticles modified carbon paste electrode (GNCPE). The electrochemical behavior of GEM has been investigated by using cyclic voltammetry (CV) and differential pulse...

Journal: :analytical and bioanalytical chemistry research 2014
ali kamal attia mona abd-elmoety amr m badawy abd-elazis abd-elaleem samar g abd-elhamid

a simple, precise, inexpensive and sensitive voltammetric method has been developed for the determination of gemifloxacin mesylate (gem) in the presence of tween 80 in the bulk, farmaceutical dosage forms and human urine at gold nanoparticles modified carbon paste electrode (gncpe). the electrochemical behavior of gem has been investigated by using cyclic voltammetry (cv) and differential pulse...

The aim of the study was to study the PK of AST2818 tablets after one oral dose in healthymale subjects on an empty stomach and in a postprandial state and to evaluate the effect of food onAST2818 bioavailability. Sixteen healthy Chinese male subjects were randomly divided into twogroups: a fasting-postprandial group and a postprandial-fasting group. T...

Journal: :international journal of hematology-oncology and stem cell research 0
gholamreza bahoush pediatric hematology-oncology department, ali-asghar children's hospital, iran university of medical sciences, tehran, iran mardavizh albouyeh pediatric hematology-oncology department, shohada general hospital, shahid-beheshti university of medical sciences, tehran, iran parvaneh vossough 1pediatric hematology-oncology department, ali-asghar children's hospital, iran university of medical sciences, tehran, iran

introduction: imatinib mesylate is a selective inhibitor of tk and is considered now to be the frontline therapeutic agent during the chronic phase of cml. we have evaluated the efficacy of it on children with chronic-phase of cml. patients and methods: in a clinical trial study over the past 3 years, 14 patients (8 females and 6 males, 2.5-14 years old) were admitted with a diagnosis of cml. s...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید